Zoladex Implant
NDC Package 70720-950-36

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Zoladex (goserelin) implants is goserelin is used in men to treat prostate cancer. This formulation utilizes a implant delivery system. Marketed by Tersera Therapeutics Llc, this product is identified by NDC 70720-950 and is authorized under FDA application NDA019726.

Identification & Billing

NDC Package Code
70720-950-36
Package Description
1 POUCH in 1 CARTON / 1 SYRINGE in 1 POUCH / 1 IMPLANT in 1 SYRINGE
Product Code
70720-950
11-Digit Billing Format
70720095036
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zoladex
Non-Proprietary Name
Goserelin
Substance Name
Goserelin Acetate
Dosage Form
Implant - A material containing drug intended to be inserted securely of deeply in a living site for growth, slow release, or formation of an organic union.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
GOSERELIN ACETATE 3.6 mg/1
Pharmacologic Class
Usage Information
Goserelin is used in men to treat prostate cancer. It is used in women to treat certain breast cancers or a certain uterus disorder (endometriosis). It is also used in women to thin the lining of the uterus (endometrium) in preparation for a procedure to treat abnormal uterine bleeding. Talk to your doctor about the risks and benefits of treatment. Goserelin is similar to a natural hormone made by the body (luteinizing hormone releasing hormone-LHRH). It works by decreasing testosterone hormones in men and estrogen hormones in women. This effect helps to slow or stop the growth of certain cancer cells and uterine tissue that need these hormones to grow and spread.

Regulatory & Marketing

Labeler Name
Tersera Therapeutics Llc
Product Type
Human Prescription Drug
FDA Application #
NDA019726
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-31-2018
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9202
Source: PDAC
GOSERELIN ACETATE IMPLANT, PER 3.6 MG
HCPCS Dosage 3.6 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70720-950-36 identifies a specific commercial package of 1 pouch in 1 carton / 1 syringe in 1 pouch / 1 implant in 1 syringe of Zoladex, a human prescription drug labeled by Tersera Therapeutics Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This implant is formulated for subcutaneous use and contains goserelin acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Tersera Therapeutics Llc on March 31, 2018. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Goserelin is used in men to treat prostate cancer. It is used in women to treat certain breast cancers or a certain uterus disorder (endometriosis). It is also used in women to thin the lining of the uterus (endometrium) in preparation for a procedure to treat abnormal uterine bleeding. Talk to your doctor about the risks and benefits of treatment. Goserelin is similar to a natural hormone made by the body (luteinizing hormone releasing hormone-LHRH). It works by decreasing testosterone hormones in men and estrogen hormones in women. This effect helps to slow or stop the growth of certain cancer cells and uterine tissue that need these hormones to grow and spread.

How is this Tersera Therapeutics Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70720095036. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70720-950-36
11-Digit CMS (5-4-2)
70720-0950-36

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.